Broadwood Capital Inc Q3 2022 vs. Q4 2022 13F Holdings Comparison
Ava Hoppe | 9 May, 2023
Broadwood Capital Inc is a hedge fund investment firm based in New York City. This article will compare its Q3 2022 and Q4 2022 13F holdings, which are public disclosures required by the Securities and Exchange Commission (SEC). The following is a summary of the holdings, changes, and trends between the two quarters.
MNST - Monster Beverage Corp New
Broadwood Capital Inc maintained its position in Monster Beverage Corp New at 4,656,488 shares, with a value of $404,928 in Q3 2022, and $472,773 in Q4 2022, a 16.8% increase.
STAA - Staar Surgical Co
Broadwood Capital Inc increased its holdings in Staar Surgical Co from 8,592,007 shares in Q3 2022 to 8,783,082 shares in Q4 2022, a 2.2% increase. However, the value of the holdings decreased from $606,166 in Q3 2022 to $426,330 in Q4 2022, a 29.7% decline.
AXON - Axon Enterprise Inc
Broadwood Capital Inc maintained its position in Axon Enterprise Inc at 760,062 shares, with a value of $87,977 in Q3 2022 and $126,117 in Q4 2022, a 43.4% increase.
IWM - Ishares Tr
Broadwood Capital Inc maintained its position in Ishares Tr at 690,000 shares, with a value of $113,795 in Q3 2022 and $120,308 in Q4 2022, a 5.7% increase.
LCTX - Lineage Cell Therapeutics In
Broadwood Capital Inc maintained its position in Lineage Cell Therapeutics In at 34,935,485 shares, with a value of $39,477 in Q3 2022 and $40,874 in Q4 2022, a 3.5% increase.
OCX - Oncocyte Corp
Broadwood Capital Inc maintained its position in Oncocyte Corp at 23,353,697 shares, with a value of $17,048 in Q3 2022 and $7,494 in Q4 2022, a 56% decrease.
AGE - Agex Therapeutics Inc
Broadwood Capital Inc maintained its position in Agex Therapeutics Inc at 2,997,156 shares, with a value of $1,683 in Q3 2022 and $1,654 in Q4 2022, a 1.7% decrease.
BTRS Holdings Inc
Broadwood Capital Inc sold all of its 4,229,652 shares in BTRS Holdings Inc in Q4 2022, down from 4,229,652 shares in Q3 2022. The value of the holdings was $39,167 in Q3 2022 and $0 in Q4 2022, a 100% decrease.
In conclusion, Broadwood Capital Inc increased its holdings in four stocks, maintained its positions in four stocks, and sold all of its holdings in one stock between Q3 2022 and Q4 2022. Despite the fluctuations in value, Broadwood Capital Inc seems to believe in the long-term potential of these stocks.
Other Posts
- The Surprising Winners and Losers of Legacy Advisors' Q4 2022 vs. Q1 2023 13F Holdings Comparison
- Asymmetry Capital Management's 13F Holdings: Insights and Analysis
- Pave America Strengthens Presence in Atlanta with Partnership with Magnum Paving
- Atlantic Investment Management, Inc. Q3 vs Q4 2022: Analyzing 13F Changes
- Point View Wealth Management's Q3-Q4 2020 13F Holdings Comparison Reveals Major Portfolio Changes with Implications for Fund Asset Values.
- Distributed Ventures Closes $100M Fund and Plans To Accelerate Growth with Key Leadership Hire
- H2O Innovation: Advancing Water Solutions with Ember Acquisition
- Comparing Plante Moran Financial Advisors' Q3 and Q4 2022 Holdings: Which Stocks Did They Change?
- Capital Insight Q4 2022 vs. Q1 2023: A Comprehensive Look at the Holdings Comparison
- Comparing Pomelo Capital LLC 13F Holdings in Q2 and Q3 2018